B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01846923
Recruitment Status : Unknown
Verified May 2013 by Vana Spoulou, Aghia Sophia Children's Hospital of Athens. Recruitment status was: Active, not recruiting
First Posted : May 6, 2013
Last Update Posted : May 6, 2013
Aghia Sophia Children's Hospital of Athens
Information provided by (Responsible Party):
Vana Spoulou, Aghia Sophia Children's Hospital of Athens
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
older than 18 years
no previously recorded allergy to PCV
no intravenous immunoglobulin (IVIG) given within the previous 6 months
no other vaccine given within the previous 6 months